These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29760306)

  • 1. Necessity for a Significant Maintenance Dosage Reduction of Voriconazole in Patients with Severe Liver Cirrhosis (Child-Pugh Class C).
    Yamada T; Imai S; Koshizuka Y; Tazawa Y; Kagami K; Tomiyama N; Sugawara R; Yamagami A; Shimamura T; Iseki K
    Biol Pharm Bull; 2018 Jul; 41(7):1112-1118. PubMed ID: 29760306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective, multicenter study of voriconazole trough concentrations and safety in patients with Child-Pugh class C cirrhosis.
    Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
    J Clin Pharm Ther; 2018 Dec; 43(6):849-854. PubMed ID: 29893015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh class B and C cirrhosis: A multicenter study.
    Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
    Int J Infect Dis; 2018 Jul; 72():49-54. PubMed ID: 29793038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using Child-Pugh Class to Optimize Voriconazole Dosage Regimens and Improve Safety in Patients with Liver Cirrhosis: Insights from a Population Pharmacokinetic Model-based Analysis.
    Wang T; Yan M; Tang D; Dong Y; Zhu L; Du Q; Sun D; Xing J; Dong Y
    Pharmacotherapy; 2021 Feb; 41(2):172-183. PubMed ID: 33064889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic Drug Monitoring of Voriconazole in Children from a Tertiary Care Center in China.
    Hu L; Dai TT; Zou L; Li TM; Ding XS; Yin T
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30150475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis.
    Carbonara S; Regazzi M; Ciracì E; Villani P; Stano F; Cusato M; Heichen M; Monno L
    Ann Pharmacother; 2009 May; 43(5):978-84. PubMed ID: 19383934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of intravenous voriconazole in patients with liver dysfunction: A prospective study in the intensive care unit.
    Lin XB; Huang F; Tong L; Xia YZ; Wu JJ; Li J; Hu XG; Liang T; Liu XM; Zhong GP; Cai CJ; Chen X
    Int J Infect Dis; 2020 Apr; 93():345-352. PubMed ID: 32109625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic model-guided optimization of intravenous voriconazole dosing regimens in critically ill patients with liver dysfunction.
    Lin XB; Lui KY; Guo PH; Liu XM; Liang T; Hu XG; Tong L; Wu JJ; Xia YZ; Chen P; Zhong GP; Chen X; Cai CJ
    Pharmacotherapy; 2022 Jan; 42(1):23-33. PubMed ID: 34655497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients.
    Yasu T; Konuma T; Kato S; Kurokawa Y; Takahashi S; Tojo A
    Ann Hematol; 2016 Oct; 95(11):1845-51. PubMed ID: 27535751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Voriconazole dosing and therapeutic drug monitoring in children: experience from a paediatric tertiary care centre.
    Boast A; Curtis N; Cranswick N; Gwee A
    J Antimicrob Chemother; 2016 Jul; 71(7):2031-6. PubMed ID: 27009030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of total and free voriconazole in human plasma: Application to pharmacokinetic study and therapeutic monitoring.
    Resztak M; Kosicka K; Zalewska P; Krawiec J; Główka FK
    J Pharm Biomed Anal; 2020 Jan; 178():112952. PubMed ID: 31708268
    [No Abstract]   [Full Text] [Related]  

  • 12. Therapeutic drug monitoring and safety of voriconazole in elderly patients.
    Cheng L; Xiang R; Liu F; Li Y; Chen H; Yao P; Sun F; Xia P
    Int Immunopharmacol; 2020 Jan; 78():106078. PubMed ID: 31830620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Voriconazole Trough Concentrations in Patients with Child-Pugh Class C Cirrhosis: A Prospective Study.
    Zhao Y; Hou J; Xiao Y; Wang F; Zhang B; Zhang M; Jiang Y; Li J; Gong G; Xiang D; Yan M
    Antibiotics (Basel); 2021 Sep; 10(9):. PubMed ID: 34572712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose optimisation of voriconazole with therapeutic drug monitoring in children: a single-centre experience in China.
    Liu L; Zhou X; Wu T; Jiang H; Yang S; Zhang Y
    Int J Antimicrob Agents; 2017 Apr; 49(4):483-487. PubMed ID: 28159657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.
    Soler-Palacín P; Frick MA; Martín-Nalda A; Lanaspa M; Pou L; Roselló E; de Heredia CD; Figueras C
    J Antimicrob Chemother; 2012 Mar; 67(3):700-6. PubMed ID: 22190607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics of Voriconazole and Optimization of Dosage Regimens Based on Monte Carlo Simulation in Patients With Liver Cirrhosis.
    Ren QX; Li XG; Mu JS; Bi JF; Du CH; Wang YH; Zhu H; Lv P; Zhao QG
    J Pharm Sci; 2019 Dec; 108(12):3923-3931. PubMed ID: 31562869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of sustained high plasma trough concentration of voriconazole with the incidence of hepatotoxicity.
    Suzuki Y; Tokimatsu I; Sato Y; Kawasaki K; Sato Y; Goto T; Hashinaga K; Itoh H; Hiramatsu K; Kadota J
    Clin Chim Acta; 2013 Sep; 424():119-22. PubMed ID: 23747486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring of voriconazole after intravenous administration in infants and children with primary immunodeficiency.
    Gerin M; Mahlaoui N; Elie C; Lanternier F; Bougnoux ME; Blanche S; Lortholary O; Jullien V
    Ther Drug Monit; 2011 Aug; 33(4):464-6. PubMed ID: 21743382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of therapeutic drug monitoring of voriconazole in a pediatric population.
    Brüggemann RJ; van der Linden JW; Verweij PE; Burger DM; Warris A
    Pediatr Infect Dis J; 2011 Jun; 30(6):533-4. PubMed ID: 21127454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic and Pharmacodynamic Properties of Oral Voriconazole in Patients with Invasive Fungal Infections.
    Wang T; Xie J; Wang Y; Zheng X; Lei J; Wang X; Dong H; Yang Q; Chen L; Xing J; Dong Y
    Pharmacotherapy; 2015 Sep; 35(9):797-804. PubMed ID: 26406771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.